FOR SALE: BigPharma Market Report on Infectious Disease & Vaccines - ONLY $15,200!

From "FierceVaccines," a weekly update on the vaccine industry.

Editor-in-Chief: John Carroll. Editor: Maureen Martino. Associate Editor: Calisha Myers. Publisher: Arsalan Arif.

New to FierceVaccines? Sign up for free at www.fiercevaccines.com
------------------------------------------------------------------

Report Index

Infectious Diseases Vaccine Market Overview: Key Companies and Strategies
Quantity in Basket: none

Price: $15,200.00

Report Format: PDF
Date Published: 18-Dec-08
Product Type: Premium Report
Table of Contents: View Table of Contents

Introduction
Long being regarded as an unattractive market, vaccines have re-emerged as successful growth driver for Big Pharma. The launch and rapid uptake of novel, high-price products such as Wyeth's Prevnar or Merck & Co's Gardasil, along with the emergence of novel vaccine technologies and favourable legislation have brought vaccines back into the main focus of pharmaceutical and biotech companies.

Scope

Market overview with current market assessment in terms of leading players, brands and geographies

In-depth analyses of the leading 5 players' portfolios, R&D pipelines, sales trends, geographic spread, licensing patterns and strategic outlook

Discussion of key developments shaping the sector: new technologies, indications and geographies

Snapshot profiles of second tier companies in the sector: strength in specialties

Report Highlights

With the exception of influenza, only two to three vaccine manufacturers compete for each disease. This lack of competition combined with public health requirements to guarantee a stable supply of vaccines has resulted in a recent upward shift of vaccine prices for specialty vaccines.

The most significant threat to the oligopoly of the Big 5 in the vaccines market comes from companies from emerging markets, which have large manufacturing capacities for biologics and are able to produce even complex substances like vaccines at low costs.

While vaccine sales have grown at a CAGR of 32% between 2004 and 2007 and shown an annual growth rate of 46% between 2006 and 2007, overall pharmaceutical sales have grown much more slowly, with both the 2004-2007 CAGR as well as the growth rate between 2006 and 2007 only reaching 8%.

Reasons to Purchase

Get a comprehensive, insightful commercial overview of the vaccines market

Learn about the strategies of the Big 5 players, their strengths, weaknesses, similarities and differences

Gain insight into the future directions and growing strategic importance of vaccines for Big Pharma

Table of Contents

Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In times of crisis, Big Pharma turns to vaccines - Market overview for the vaccines sector. Profiles of the 5 major vaccine companies, analyzing strategic directions in terms R&D and licensing, portfolio and pipeline breadth and depth as well as other individual strengths & weaknesses

Product Code: dmhc2457

Publication Date: 18-Dec-2008


--------------------------------------------------------------------------------

Overview

Introduction

Long being regarded as an unattractive market, vaccines have re-emerged as successful growth driver for Big Pharma. The launch and rapid uptake of novel, high-price products such as Wyeth's Prevnar or Merck & Co's Gardasil, along with the emergence of novel vaccine technologies and favourable legislation have brought vaccines back into the main focus of pharmaceutical and biotech companies.

Scope

· Market overview with current market assessment in terms of leading players, brands and geographies

· In-depth analyses of the leading 5 players' portfolios, R&D pipelines, sales trends, geographic spread, licensing patterns and strategic outlook

· Discussion of key developments shaping the sector: new technologies, indications and geographies

· Snapshot profiles of second tier companies in the sector: strength in specialties

Highlights

With the exception of influenza, only two to three vaccine manufacturers compete for each disease. This lack of competition combined with public health requirements to guarantee a stable supply of vaccines has resulted in a recent upward shift of vaccine prices for specialty vaccines.

The most significant threat to the oligopoly of the Big 5 in the vaccines market comes from companies from emerging markets, which have large manufacturing capacities for biologics and are able to produce even complex substances like vaccines at low costs.

While vaccine sales have grown at a CAGR of 32% between 2004 and 2007 and shown an annual growth rate of 46% between 2006 and 2007, overall pharmaceutical sales have grown much more slowly, with both the 2004-2007 CAGR as well as the growth rate between 2006 and 2007 only reaching 8%.

Reasons to Purchase

· Get a comprehensive, insightful commercial overview of the vaccines market

· Learn about the strategies of the Big 5 players, their strengths, weaknesses, similarities and differences

· Gain insight into the future directions and growing strategic importance of vaccines for Big Pharma


--------------------------------------------------------------------------------

ABOUT DATAMONITOR HEALTHCARE
2

About the Infectious diseases pharmaceutical analysis team
2

CHAPTER 1 EXECUTIVE SUMMARY
3

Strategic scoping and focus
3

Datamonitor insight into the disease market
3

Related reports
8

CHAPTER 2 MARKET DEFINITION
10

Market definition for this report
10

CHAPTER 3 MARKET OVERVIEW
12

Summary
12

Vaccines have emerged as key revenue drivers for Big Pharma
13

The emergence of new technologies has increased the possibilities for vaccine development
13

The success stories of Prevnar and Gardasil fuel hopes for further vaccine blockbusters
15

New legislation in the US has decreased the risks of litigation for vaccine manufacturers
18

The high entry hurdles for generics manufacturers make vaccines an attractive sector in times of the decline of the traditional blockbuster model
20

Upholding the strong growth of the vaccine sector as a whole will be the key challenge in the coming decade
23

Current market assessment
24

Five big companies dominate the vaccines market
24

The global vaccine market is growing very fast and the importance of vaccines for pharmaceutical portfolios is increasing
25

Over the last four years, approvals of novel vaccines as well as consolidation have shaped the global vaccine market
28

The US remain the main market for vaccines in 2007
29

Wyeth's Prevnar and Merck & Co's Gardasil have both reached blockbuster status
30

Snapshot of other important vaccines players
31

AstraZeneca: holding on to MedImmune's heritage?
33

Bavarian Nordic: niche player in biodefense
33

Baxter - strong manufacturing capacity as key opportunity
33

CSL: controlling the Australian vaccines market
34

Crucell: attractive dual business model
35

Emergent BioSolutions: focusing on biodefense
35

Intercell: the multi-partner company
36

Pfizer: building on DNA vaccines and adjuvants
37

Solvay: influenza as key focus
37

Opportunities and threats
38

Opportunities
39

Development of vaccines for novel indications
39

Development of new technologies
41

Expansion to emerging and developing markets
41

Increasing awareness and "disease marketing"
43

Threats
44

Cost containment
44

Regulatory requirement for increasingly large trials increases upfront investments and development times
45

Low-cost manufacturers from emerging markets could shake up the sector and undercut prices
46

Negative publicity and public scares through anti-vaccination activists
48

CHAPTER 4 MERCK & CO - THE INNOVATOR
51

Summary
51

Strategic overview
52

History of vaccines division
52

Sales performance
55

Geographic spread
56

Seasonality
57

Role of vaccines in overall company portfolio
58

Portfolio analysis
60

Gardasil
61

RotaTeq
64

Zostavax
66

Hepatitis franchise
68

Other viral vaccines
70

Other vaccines
71

Pipeline analysis
73

Heplisav
76

V710
78

V503
79

V419
79

V950
80

Deals and alliances
80

Product deals
81

In-licensing of Heplisav from Dynavax Technologies
83

Collaboration with Intercell regarding staphylococcal vaccines
83

In-licensing of Gardasil from CSL
84

Development collaborations with PATH and the Indian Council of Medical Research
84

M&A, distribution and marketing agreements
85

Technology deals
85

In-licensing of Idera's TLR7, 8, 9 adjuvant candidates for use in vaccines against oncology, infectious diseases and Alzheimer's disease
86

Research collaboration with Iomai regarding Iomai's transdermal patch delivery technology
87

Grants and government contracts
87

Strategic outlook
88

Strengths: Merck & Co's strong portfolio of novel, high-price vaccines will continue to provide large vaccine revenues
89

Weaknesses: late-stage failures have thinned Merck & Co's vaccine pipeline
89

Opportunities: further geographic expansion of Merck & Co's novel vaccines portfolio could result in substantial revenue increases
91

Threats: competition for RotaTeq and Gardasil is emerging
92

CHAPTER 5 SANOFI PASTEUR - THE CUSTOMIZER
93

Summary
93

Strategic overview
94

History of vaccines division
94

Sales performance
98

Seasonality
99

Role of vaccines in overall company portfolio
99

Portfolio analysis
101

Influenza vaccine franchise
102

Pediatric combination franchise
105

Adult/adolescent booster franchise
109

Meningitis/pneumonia franchise
111

Travel, endemic, MMR vaccine franchise
114

Other vaccines
116

Pipeline analysis
118

Influenza
123

Pediatric and adolescent combination vaccines
124

Meningitis/pneumonia
125

Travelers and endemic vaccines
126

Other vaccines
128

Deals and alliances
130

Product deals
130

Licensing agreement with Crucell regarding cell-based influenza vaccines and related technical services agreement with Lonza
133

Manufacturing and supply agreement with M.P. Chumakov Institute of Poliomyelitis and Virus Encephalitides regarding polio vaccine for Russia
133

Research and license agreement with Statens Serum Institut regarding tuberculosis vaccine candidate
133

M&A, distribution and marketing agreements
134

Acquisition of Acambis
135

Joint venture with Daiichi Sankyo for the Japanese market
136

Technology deals
136

Licensing of Becton-Dickinson's micro-delivery technology
139

Grants and government contracts
139

Strategic outlook
141

Strengths: ongoing leadership in important flu and pediatric combination sectors
142

Weaknesses: focus on follow-on has resulted in lack of innovation
143

Opportunities: hidden pipeline gems with blockbuster potential
144

Threats: Menactra's monopoly expected to fall
144

CHAPTER 6 GLAXOSMITHKLINE - THE ALL-ROUNDER
146

Summary
146

Strategic overview
147

History of vaccine division
147

Sales performance
150

Geographic spread
151

Seasonality
152

Role of vaccines in overall company portfolio
153

Portfolio analysis
155

Infanrix franchise
156

Hepatitis franchise
159

Influenza franchise
160

Cervarix
163

Rotarix
165

Other vaccines
166

Pipeline analysis
167

Meningitis
170

Pneumococcal disease
171

Influenza
171

Travel vaccines and tuberculosis
172

Cancer
172

Deals and alliances
173

Product deals
173

In-licensing of two Alzheimer vaccine candidates from Affiris
175

In-licensing of MAGE-A3 and other tumor antigens from the Ludwig Institute of Cancer Research
175

In-licensing of meningitis antigens and IP from Imclone
175

In-licensing of Rotarix from AVANT Immunotherapeutics
176

Strategic alliance with MedImmune for the development of Cervarix
176

M&A, public-private partnerships, distribution and marketing agreements
176

Acquisition of ID Biomedical
179

Acquisition of Corixa Corporation
180

Promotion Service Agreement with Sinovac Biotech and establishment of an exclusive cooperation agreement with Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. (NIBT)
180

Technology deals
181

Licensing of MedImmune's reverse genetics technology for influenza
183

Grants and government contracts
183

Strategic outlook
184

Strengths: commercializing on a continuing strong portfolio
186

Weaknesses: suboptimal US penetration constitutes major revenue limitation
186

Opportunities: strong pipeline to drive future revenues
187

Threats: FDA's attitude towards novel adjuvants unlikely to change soon
188

CHAPTER 7 WYETH - THE ONE HIT WONDER
190

Summary
190

Strategic overview
191

History of vaccines division
191

Sales performance
193

Geographic spread
194

Seasonality
195

Role of vaccines in overall company portfolio
196

Portfolio analysis
198

Prevnar
199

Pipeline analysis
201

Prevnar 13
203

ACC-001
204

MnB rLP2086
204

Deals and alliances
205

Product deals
205

License agreement with RIVM for meningitis B vaccine
206

Alliance with Elan for development of new drugs to treat Alzheimer's disease
206

M&A, public-private partnerships
207

Equity Investment in Alphavax
208

Technology deals
208

In-licensing of Inhibitex's MSCRAMM (Microbial Surface Components Recognizing Adhesive Matrix Molecules) protein technology
210

Inlicensing of Inovio's DNA delivery technology
210

Grants and government contracts
210

Strategic outlook
211

Strengths: Wyeth will continue to dominate the pneumococcal vaccine market
212

Weaknesses: strong reliance on Prevnar franchise as sole revenue generator
213

Opportunities: strong focus on new geographies and target groups
214

Threats: emerging competitors in key revenue sectors
214

CHAPTER 8 NOVARTIS - THE NEWCOMER
216

Summary
216

Strategic overview
217

History of vaccines division
217

Sales performance
220

Geographic spread
221

Seasonality
222

Role of vaccines in overall company portfolio
223

Portfolio analysis
224

Influenza vaccine franchise
225

Travel vaccine franchise
227

Meningitis vaccines
228

Pediatric/adult DTP/polio/Hib vaccines
229

Pipeline analysis
230

Meningitis
234

Influenza
235

Novel therapeutic vaccines
236

CAD106 (Alzheimer's disease, Phase II)
236

Nic002 (nicotine dependence, Phase II)
236

Others
237

Deals and alliances
238

Product deals
238

Strategic partnership with Intercell
241

Marketing and distribution agreement for Intercell's Ixiaro
241

In-licensing of CAD106 and Nic002 from Cytos Biotechnology
242

M&A, distribution and marketing agreements
242

Acquisition of Chiron
244

Acquisition of PowderJect and Spin-off of PowderMed by Chiron
245

Divestment of SBL Vaccin AB
246

Technology deals
246

Grants and government contracts
247

Strategic outlook
249

Strengths: Novartis has a strong influenza portfolio and excellent science
250

Weaknesses: two years after the acquisition of Chiron, Novartis's vaccine division is still fragmented
251

Opportunities: Menveo and Men B as potential blockbusters
251

Threats: competition in the meningitis space is fierce
252

BIBLIOGRAPHY
253

Company financial reports
253

Merck & Co
253

Sanofi Pasteur
253

GlaxoSmithKline
253

Wyeth
254

Novartis
254

Further literature
254

APPENDIX
263

Contributing experts
263

Report methodology
263

About Datamonitor
264

About Datamonitor Healthcare
264

About the Infectious Diseases analysis team
265

Key therapy team members
266

Holger Rovini, Head of Respiratory and Infectious Diseases
266

Hedwig Kresse, Senior Analyst, Infectious Diseases
266

Disclaimer
268

List of Tables


Table 1: Vaccine sales and growth rates of the top five vaccine manufacturers, 2004-9M2008
26

Table 2: Sales breakdown of the four best-selling vaccines, 2004-9M 2008
31

Table 3: Recent key mergers and acquisitions in the vaccines industry, December 2008
32

Table 4: Summary of opportunities and threats in the vaccines market, 2008
39

Table 5: Merck & Co - vaccine portfolio overview, December 2008
61

Table 6: Merck & Co - Gardasil product overview
62

Table 7: Merck & Co - RotaTeq product overview
64

Table 8: Merck & Co - Zostavax product overview
66

Table 9: Merck & Co - hepatitis franchise product overview
68

Table 10: Merck & Co - other viral vaccines product overview
70

Table 11: Merck & Co - other vaccines product overview
72

Table 12: Merck & Co - vaccine pipeline overview, December 2008
74

Table 13: Merck & Co - key vaccine product deals, December 2008
82

Table 14: Merck & Co - Vaccine joint venture with Sanofi Pasteur
85

Table 15: Merck & Co - key vaccine technology deals, December 2008
86

Table 16: Merck & Co vaccines - SWOT analysis, December 2008
88

Table 17: Sanofi Pasteur - vaccine portfolio overview, December 2008
102

Table 18: Sanofi Pasteur - influenza vaccine franchise product overview
103

Table 19: Sanofi Pasteur - pediatric combination vaccine franchise key product overview
107

Table 20: Sanofi Pasteur - booster vaccine franchise product overview
110

Table 21: Sanofi Pasteur - meningitis/pneumonia vaccine franchise product overview
112

Table 22: Sanofi Pasteur - traveler/endemic vaccine franchise product overview
115

Table 23: Sanofi Pasteur - vaccine pipeline overview, December 2008
119

Table 24: Sanofi Pasteur - Key vaccine product deals (1); December 2008
131

Table 25: Sanofi Pasteur - Key vaccine product deals (2); December 2008
132

Table 26: Sanofi Pasteur - key vaccine M&A, public-private partnerships, distribution/marketing agreements, December 2008
135

Table 27: Sanofi Pasteur - key vaccine technology deals, December 2008
138

Table 28: Sanofi Pasteur - key grants and government contracts for vaccines, December 2008
140

Table 29: Sanofi Pasteur - SWOT analysis, December 2008
142

Table 30: GlaxoSmithKline - vaccine portfolio overview, December 2008
156

Table 31: GlaxoSmithKline - Infanrix franchise product overview
157

Table 32: GlaxoSmithKline - DTP adolescent booster product overview
157

Table 33: GlaxoSmithKline - hepatitis franchise product overview
159

Table 34: GlaxoSmithKline - influenza vaccine franchise product overview
162

Table 35: GlaxoSmithKline - other vaccines, overview
167

Table 36: GlaxoSmithKline - vaccine pipeline overview, December 2008
168

Table 37: GlaxoSmithKline - key vaccine product deals; December 2008
174

Table 38: GlaxoSmithKline - key vaccine M&A, public-private partnerships, distribution/marketing agreements, December 2008
178

Table 39: GlaxoSmithKline - key vaccine technology deals, December 2008
182

Table 40: GlaxoSmithKline - key grants and government contracts for vaccines, December 2008
184

Table 41: GlaxoSmithKline vaccines - SWOT analysis, December 2008
185

Table 42: Wyeth - vaccines pipeline, December 2008
202

Table 43: Wyeth - key vaccine product deals, December 2008
206

Table 44: Wyeth - key vaccine M&A, public-private partnerships, distribution/marketing agreements, December 2008
208

Table 45: Wyeth - key vaccine technology deals, December 2008
209

Table 46: Wyeth - key grants and government contracts for vaccines, December 2008
211

Table 47: Wyeth vaccines - SWOT analysis, December 2008
212

Table 48: Novartis - vaccine portfolio overview; December 2008
225

Table 49: Novartis - Influenza vaccine franchise product overview
226

Table 50: Novartis - travel vaccine franchise key product overview
227

Table 51: Novartis - meningococcal vaccine franchise product overview
228

Table 52: Novartis - clinical vaccine pipeline overview, December 2008
231

Table 53: Novartis - key vaccine product deals, December 2008
240

Table 54: Novartis - key vaccine M&A, public-private partnerships, distribution/marketing agreements, December 2008
244

Table 55: Novartis - key vaccine technology deals, December 2008
247

Table 56: Novartis - key grants and government contracts for vaccines, December 2008
248

Table 57: Novartis - SWOT analysis, December 2008
249

List of Figures


Figure 1: Comparison of IMS-reported versus company-reported global sales data for vaccines, 2007
10

Figure 2: Prevnar: global sales 2001-9M2008
16

Figure 3: Gardasil: sales 2004-9M2008
17

Figure 4: National Vaccine Injury Compensation Program - petition and award statistics, 1990-2008
20

Figure 5: Comparison of lifecycles of pharmaceuticals and vaccines
22

Figure 6: Market growth cycle for vaccines
23

Figure 7: Market shares of the five key vaccine players in total vaccine sales, 2004 versus 2007
24

Figure 8: Combined vaccine sales of the top five vaccine manufacturers, 2004-9M2008
25

Figure 9: Vaccines versus overall pharmaceutical sales, 2007
27

Figure 10: Vaccine sales as share of overall company pharmaceutical sales, 2004-9M2008
28

Figure 11: Key events impacting the vaccines market, 2004-08
29

Figure 12: 2007 vaccine sales of Merck & Co, GlaxoSmithKline, Wyeth, Novartis and Sanofi Pasteur MSD by geography
30

Figure 13: Share of leading vaccines on a product basis, 2004-2007
31

Figure 14: Birth cohort sizes - seven major markets versus BRIC countries
42

Figure 15: Possible strategies for penetration of emerging markets
43

Figure 16: Public sector costs of routine childhood immunization per child, US, 1975-2008
44

Figure 17: Number of enrolled patients in Phase III trials for selected vaccines
46

Figure 18: Presence of local/regional vaccine manufacturers in emerging geographies
47

Figure 19: Reported measles cases and MMR vaccination coverage in England, 1996--2007
49

Figure 20: Merck & Co - vaccines pedigree, 2008
54

Figure 21: Merck & Co - total vaccine sales, 2004-2008; Q1-Q3
56

Figure 22: Merck & Co vaccine sales - geographic spread, 2004-9M2008
57

Figure 23: Merck & Co - total vaccine sales, by quarter, 2006-9M2008
58

Figure 24: Merck & Co - vaccine sales as share of overall company pharmaceutical sales, 2004-9M2008
59

Figure 25: Merck & Co - vaccines versus overall pharmaceutical sales, 2007
60

Figure 26: Merck & Co - Gardasil sales by geography, 2004-9M2008
62

Figure 27: Merck & Co - RotaTeq sales by geography, 2004-9M2008
65

Figure 28: Merck & Co - Zostavax sales by geography, 2004-9M2008
67

Figure 29: Merck & Co - hepatitis franchise sales by geography, 2004-9M2008
69

Figure 30: Merck & Co - other viral vaccines sales by geography, 2004-9M2008
71

Figure 31: Merck & Co - other vaccines sales by geography, 2004-9M2008
73

Figure 32: Merck & Co - overlap between marketed vaccines portfolio and pipeline vaccines, December 2008
75

Figure 33: Merck & Co - clinical vaccines pipeline depth, December 2008
76

Figure 34: Sanofi Pasteur - history of vaccines division
96

Figure 35: Sanofi Pasteur - vaccines pedigree, 2008
97

Figure 36: Sanofi Pasteur - total vaccine sales, 2004-9M 2008
98

Figure 37: Sanofi Pasteur - total vaccine sales, by quarter, 2006-9M2008
99

Figure 38: Sanofi Aventis - vaccine sales as share of overall company pharmaceutical sales, 2004-9M2008
100

Figure 39: Sanofi Aventis - vaccines versus overall pharmaceutical sales, 2007
101

Figure 40: Sanofi Pasteur - influenza vaccine franchise sales, 2004-9M2008
104

Figure 41: Sanofi Pasteur - pediatric combination vaccine franchise sales, 2004-9M2008
108

Figure 42: Sanofi Pasteur - booster vaccine franchise sales, 2004-9M2008
110

Figure 43: Sanofi Pasteur - meningitis/pneumonia vaccine franchise sales, 2004-9M2008
113

Figure 44: Sanofi Pasteur - traveler/endemic vaccine franchise sales, 2004-9M2008
116

Figure 45: Sanofi Pasteur - other vaccine sales, 2004-9M2008
117

Figure 46: Sanofi Pasteur - share of Sanofi Pasteur MSD joint venture sales by vaccine class, 2004-9M2008
118

Figure 47: Sanofi Pasteur - clinical vaccines pipeline depth and breadth, December 2008
121

Figure 48: Sanofi Pasteur - overlap between marketed vaccines portfolio and pipeline vaccines, December 2008
122

Figure 49: GlaxoSmithKline - history of vaccines division
148

Figure 50: GlaxoSmithKline - vaccines pedigree, 2008
149

Figure 51: GlaxoSmithKline - total vaccine sales, 2004-9M2008
151

Figure 52: GlaxoSmithKline vaccine sales - geographic spread, 2004-9M2008
152

Figure 53: GlaxoSmithKline - total vaccine sales, by quarter, 2006-9M2008
153

Figure 54: GlaxoSmithKline - vaccine sales as share of overall company pharmaceutical sales, 2004-9M2008
154

Figure 55: GlaxoSmithKline - vaccines versus overall pharmaceutical sales, 2007
155

Figure 56: GlaxoSmithKline - Infanrix and Boostrix franchise sales by geography, 2004-9M2008
158

Figure 57: GlaxoSmithKline - hepatitis vaccine franchise sales by geography, 2004-9M2008
160

Figure 58: GlaxoSmithKline - influenza vaccine franchise sales by geography, 2004-9M2008
163

Figure 59: GlaxoSmithKline - Cervarix sales by geography, 2004-9M2008
164

Figure 60: GlaxoSmithKline - Rotarix sales by geography, 2004-9M2008
166

Figure 61: GlaxoSmithKline - overlap between marketed vaccines portfolio and pipeline vaccines, December 2008
169

Figure 62: GlaxoSmithKline - clinical vaccines pipeline depth and breadth, December 2008
170

Figure 63: GlaxoSmithKline vaccines pipeline - adjuvanted versus non-adjuvanted candidates, December 2008
188

Figure 64: Wyeth - vaccines pedigree, 2008
192

Figure 65: Wyeth - total vaccine sales (Prevnar), 2004-9M2008
193

Figure 66: Wyeth vaccine sales (Prevnar) - geographic spread, 2004-9M2008
195

Figure 67: Wyeth - total vaccine sales (Prevnar), by quarter, 2006-9M2008
196

Figure 68: Wyeth - vaccine sales (Prevnar) as share of overall company pharmaceutical sales, 2004-9M2008
197

Figure 69: Wyeth - vaccines (Prevnar) versus overall pharmaceutical sales, 2007
198

Figure 70: Wyeth - Prevnar sales by geography, 2004-9M2008
200

Figure 71: Wyeth - overlap between marketed vaccines portfolio and pipeline vaccines, December 2008
202

Figure 72: Novartis - history of vaccines division
218

Figure 73: Novartis - vaccines pedigree, 2008
219

Figure 74: Novartis- total vaccine sales, 2004-9M2008
221

Figure 75: Novartis vaccines and diagnostics sales - geographic spread, 2004-9M2008
222

Figure 76: Novartis - total vaccine and diagnostics sales, by quarter, 2006-9M2008
223

Figure 77: Novartis - vaccines and diagnostics sales as share of overall company pharmaceutical sales (excluding consumer health), 2004-9M2008
224

Figure 78: Novartis - overlap between marketed vaccines portfolio and pipeline vaccines
232

Figure 79: Novartis - clinical vaccines pipeline depth and breadth, December 2008
233



--------------------------------------------------------------------------------








If you require further information on this product or would like to purchase by invoice call our customer service number:
(+1) 800-759-0261 or Email us.



If you require assistance please Email us or call +1-800-759-0261.




Click on title above to see original article;
http://market-research-report.com/Merchant2/merchant.mvc?